Lynparza (olaparib) — CareFirst (Caremark)

Initial criteria

• For adjuvant therapy of HER2-negative, germline BRCA-mutated breast cancer after completion of neoadjuvant/adjuvant chemotherapy when ANY of the following:
• - Hormone receptor-negative breast cancer with any residual disease
• - Hormone receptor-negative breast cancer with tumor size ≥ 2 cm or any involved axillary nodes
• - Hormone receptor-positive breast cancer with ≥ 4 positive lymph nodes
• - Hormone receptor-positive breast cancer with any residual disease and CPS+EG score ≥ 3 after preoperative therapy
• OR For treatment of breast cancer with no response to preoperative systemic therapy, or recurrent unresectable (local/regional) or metastatic disease, as a single agent in members with deleterious or suspected deleterious germline BRCA mutations

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression
• Maximum treatment duration for adjuvant early-stage HER2-negative BRCA-mutated breast cancer = 1 year

Approval duration

12 months